ScienceDaily: Top News |
- Research solves mystery of memory and mood
- Preoperative statins reduce mortality in coronary artery bypass graft surgery
- American surgery patients: More pain medication, yet more pain
- No reason for laughing gas to be withdrawn from operating theaters
- Discovery could improve radiotherapy for wide range of cancers
- High cost of healthcare for UK military amputees from Afghan conflict
- 75 per cent of annual global greenhouse gas emissions covered by national targets
- Immunotherapy drug improves survival for common form of lung cancer
- Contact lens wearers: Eyes may get more infections because their 'microbiomes' have changed
- Possible new combination chemotherapy for patients with advanced prostate cancer
- Risks of whole brain radiation therapy added to radiosurgery outweigh benefits for patients with limited brain metastases
- Immunotherapy combo increases progression-free survival in advanced melanoma patients
- Gene therapy, surgery could mean eight more months for sickest brain cancer patients
- Mobile Maestro: Immersive sound reproduction system from several smart phones
Research solves mystery of memory and mood Posted: 31 May 2015 06:11 PM PDT |
Preoperative statins reduce mortality in coronary artery bypass graft surgery Posted: 31 May 2015 06:11 PM PDT |
American surgery patients: More pain medication, yet more pain Posted: 31 May 2015 06:11 PM PDT |
No reason for laughing gas to be withdrawn from operating theaters Posted: 31 May 2015 06:11 PM PDT |
Discovery could improve radiotherapy for wide range of cancers Posted: 31 May 2015 06:10 PM PDT |
High cost of healthcare for UK military amputees from Afghan conflict Posted: 31 May 2015 06:10 PM PDT |
75 per cent of annual global greenhouse gas emissions covered by national targets Posted: 31 May 2015 03:11 PM PDT |
Immunotherapy drug improves survival for common form of lung cancer Posted: 31 May 2015 03:11 PM PDT In a head-to-head clinical trial comparing standard chemotherapy with the immunotherapy drug nivolumab, researchers found that people with squamous-non-small cell lung cancer who received nivolumab lived, on average, 3.2 months longer than those receiving chemotherapy. Squamous non-small cell lung cancer accounts for 25 to 30 percent of all lung malignancies. |
Contact lens wearers: Eyes may get more infections because their 'microbiomes' have changed Posted: 31 May 2015 11:10 AM PDT |
Possible new combination chemotherapy for patients with advanced prostate cancer Posted: 31 May 2015 07:00 AM PDT |
Posted: 31 May 2015 07:00 AM PDT |
Immunotherapy combo increases progression-free survival in advanced melanoma patients Posted: 31 May 2015 07:00 AM PDT |
Gene therapy, surgery could mean eight more months for sickest brain cancer patients Posted: 31 May 2015 07:00 AM PDT As the most malignant of primary brain cancers, glioblastomas are frustratingly difficult to treat. Surgery is often risky and cannot remove all of the tumor, and chemotherapy eventually becomes ineffective for most patients. Median survival is around 15 months for patients with this tumor, and the quality of life in the last five months is often quite poor. |
Mobile Maestro: Immersive sound reproduction system from several smart phones Posted: 31 May 2015 07:00 AM PDT |
You are subscribed to email updates from Latest Science News -- ScienceDaily To stop receiving these emails, you may unsubscribe now. | Email delivery powered by Google |
Google Inc., 1600 Amphitheatre Parkway, Mountain View, CA 94043, United States |
ليست هناك تعليقات:
إرسال تعليق